Free Trial

Sionna Therapeutics (SION) Competitors

Sionna Therapeutics logo
$19.14 -0.63 (-3.19%)
As of 04:00 PM Eastern

SION vs. IMVT, CRNX, KYMR, HCM, MOR, RARE, ARWR, ALVO, MIRM, and CPRX

Should you be buying Sionna Therapeutics stock or one of its competitors? The main competitors of Sionna Therapeutics include Immunovant (IMVT), Crinetics Pharmaceuticals (CRNX), Kymera Therapeutics (KYMR), HUTCHMED (HCM), MorphoSys (MOR), Ultragenyx Pharmaceutical (RARE), Arrowhead Pharmaceuticals (ARWR), Alvotech (ALVO), Mirum Pharmaceuticals (MIRM), and Catalyst Pharmaceuticals (CPRX). These companies are all part of the "pharmaceutical products" industry.

Sionna Therapeutics vs. Its Competitors

Immunovant (NASDAQ:IMVT) and Sionna Therapeutics (NASDAQ:SION) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, media sentiment, earnings, dividends and risk.

47.1% of Immunovant shares are owned by institutional investors. 1.8% of Immunovant shares are owned by company insiders. Comparatively, 3.9% of Sionna Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Sionna Therapeutics' return on equity of 0.00% beat Immunovant's return on equity.

Company Net Margins Return on Equity Return on Assets
ImmunovantN/A -80.60% -71.89%
Sionna Therapeutics N/A N/A N/A

In the previous week, Sionna Therapeutics had 1 more articles in the media than Immunovant. MarketBeat recorded 1 mentions for Sionna Therapeutics and 0 mentions for Immunovant. Sionna Therapeutics' average media sentiment score of 1.79 beat Immunovant's score of 0.00 indicating that Sionna Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Immunovant Neutral
Sionna Therapeutics Very Positive

Immunovant currently has a consensus price target of $36.30, indicating a potential upside of 98.14%. Sionna Therapeutics has a consensus price target of $38.50, indicating a potential upside of 101.15%. Given Sionna Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Sionna Therapeutics is more favorable than Immunovant.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Immunovant
0 Sell rating(s)
3 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.82
Sionna Therapeutics
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunovantN/AN/A-$413.84M-$2.74-6.69
Sionna TherapeuticsN/AN/A-$61.69MN/AN/A

Summary

Sionna Therapeutics beats Immunovant on 8 of the 11 factors compared between the two stocks.

Get Sionna Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SION and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SION and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SION vs. The Competition

MetricSionna TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$844.46M$3.05B$5.67B$9.49B
Dividend YieldN/A2.44%4.05%4.00%
P/E RatioN/A20.8627.9419.96
Price / SalesN/A246.07396.5882.69
Price / CashN/A41.9636.1958.45
Price / BookN/A8.308.635.82
Net Income-$61.69M-$55.19M$3.24B$258.42M
7 Day Performance4.42%5.06%3.22%1.94%
1 Month Performance19.33%17.59%10.71%12.02%
1 Year PerformanceN/A7.02%34.94%20.81%

Sionna Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SION
Sionna Therapeutics
N/A$19.14
-3.2%
$38.50
+101.1%
N/A$844.46MN/A0.0035
IMVT
Immunovant
1.0913 of 5 stars
$18.17
+2.0%
$36.30
+99.8%
-34.3%$3.11BN/A-6.63120Positive News
CRNX
Crinetics Pharmaceuticals
3.6026 of 5 stars
$33.01
+3.5%
$69.50
+110.5%
-43.5%$3.09B$1.04M-8.64210
KYMR
Kymera Therapeutics
3.1557 of 5 stars
$46.72
+2.7%
$59.11
+26.5%
+6.8%$3.04B$47.07M-15.08170
HCM
HUTCHMED
2.8081 of 5 stars
$17.44
+1.8%
$19.00
+8.9%
-7.0%$3.04B$630.20M0.001,811Analyst Forecast
MOR
MorphoSys
N/A$18.96
flat
N/AN/A$2.86B$238.28M-5.45730
RARE
Ultragenyx Pharmaceutical
4.3494 of 5 stars
$27.83
+1.9%
$83.64
+200.6%
-38.0%$2.63B$560.23M-4.721,294Upcoming Earnings
ARWR
Arrowhead Pharmaceuticals
3.879 of 5 stars
$18.98
+3.7%
$43.71
+130.4%
-44.7%$2.62B$545.21M-13.55400
ALVO
Alvotech
2.8685 of 5 stars
$8.68
+3.1%
$18.00
+107.4%
-22.4%$2.62B$585.60M23.451,032
MIRM
Mirum Pharmaceuticals
3.9526 of 5 stars
$52.79
0.0%
$65.50
+24.1%
+32.0%$2.61B$336.89M-32.79140
CPRX
Catalyst Pharmaceuticals
4.9136 of 5 stars
$21.37
+0.9%
$32.83
+53.7%
+22.8%$2.61B$491.73M13.6180News Coverage
Positive News

Related Companies and Tools


This page (NASDAQ:SION) was last updated on 7/24/2025 by MarketBeat.com Staff
From Our Partners